Santhera’s Vamorolone For DMD Among Orphan Drugs Up For EU Marketing Decision
The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing authorization for a number of new products.
You may also be interested in...
The European Medicines Agency is due to decide whether to back pan-EU marketing authorization for 11 new products, including four orphan drugs.
Four new orphan medicines were among the products recommended for pan-EU marketing approval by the European Medicines Agency this week.
In a major boost for Santhera and Duchenne muscular dystrophy patients, EU regulators have backed the firm’s Agamree for children aged four years and older and a launch in Germany is scheduled for January.